Phase 3 Data for Oral Orexin Agonist in Narcolepsy Type 1 Published in NEJM
Key takeaways: Oveporexton improved mean sleep latency on the Maintenance of Wakefulness Test by 14.3 to 19.8 minutes…
Narcolepsy Drugs Market to Reach US$ 6.81 Billion by 2034 as Sleep Disorder Awareness and Innovative Therapies Drive Growth
A New Era Begins for Narcolepsy Treatment For decades, narcolepsy remained one of the most misunderstood neurological disorders.…
Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis | BMC Neurology
Study selection The preliminary search obtained 2927 articles, among which 1024 duplicates were eliminated. 28 articles were retained…
New review reveals microbiome clues to insomnia and apnea
Trillions of gut microbes may hold the key to better rest. A new review reveals how shifts in…